Skip to main content
. 2018 Mar 9;7(3):49. doi: 10.3390/jcm7030049

Table 2.

Winthrop University Hospital’s recent tigecycline experience: secondary endpoints.

Loading Doses Used n = cases (%)
None 25 (73.5%)
100 mg (IV) × 1 3 (8.8%)
200 mg (IV) × 1 2 (5.9%)
400 mg(IV) × 1 4 (11.8%)
Maintenance Doses Used
50 mg (IV) q12h 8 (23.5%)
100 mg (IV) q24h 22 (64.7%)
200 mg (IV) q24h 4 (11.8%)
Infectious Disease Consultation
Yes 28 (82.4%)
No 6 (17.6%)
Incidence of Nausea/Vomiting
Yes 6 (17.6%)
No 28 (82.4%)